New application of PTX-3 in medical detection

A PTX-3, 1. PTX-3 technology, applied in the field of biomedicine, can solve the problems of poor prognosis, recurrence, sensitivity to chemotherapeutic drugs, etc., and achieve good clinical application value

Pending Publication Date: 2021-06-08
沈阳金域医学检验所有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Patients with epithelial ovarian cancer are sensitive to chemotherapy drugs, and most advanced patients usually achieve clinical remission after receiving standard treatment, but many patients have a poor prognosis due to recurrence and drug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of PTX-3 in medical detection
  • New application of PTX-3 in medical detection
  • New application of PTX-3 in medical detection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1: Preliminary screening of differentially expressed genes in ovarian cancer

[0058] Two ovarian cancer datasets were selected using the GEO database: GSE18520 and GSE26712. The GSE18520 dataset is based on the GPL570 platform (HG-U133_Plus_2; Affymetrix Human Genome U133 Plus 2.0 Array), which contains 53 high-grade serous papillary carcinoma samples and 10 paracancerous carcinoma samples. The GSE26712 dataset is based on the GPL96 platform (HG-U133A; Affymetrix Human Genome U133A Array), which contains 10 normal ovarian epithelial samples and 185 primary ovarian cancer samples. By using the R package "limma", the differences between 20 normal ovarian samples and 238 ovarian cancer samples were analyzed. |logFC|>1.5, and p-value<0.05 were defined as differentially expressed genes. A total of 100 up-regulated genes and 228 down-regulated genes were analyzed by Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways by using t...

Embodiment 2

[0060] Example 2: Construction of weighted co-expression network for further screening of differentially expressed genes in ovarian cancer

[0061] The WGCNA software package was used to construct the gene co-expression network. The top 25% of genes in the variance plot were selected to construct a weighted co-expression network. The network modules are subdivided using the dynamic pruning tree algorithm. To test the stability of each identified module, train and test sets were randomly generated using Preserve Function Module Stability in the WGCNA package. Key modules were searched for correlations between modules and clinical characteristics assessed by the Pearson correlation test. Clinical features of the samples included normal tissue and ovarian cancer, and correlations between modules and features were calculated. Modules positively associated with ovarian cancer are thought to play a role in the pathogenesis of the disease. On the other hand, genes in modules posi...

Embodiment 3

[0063] Example 3: Survival analysis of differentially expressed genes in ovarian cancer

[0064] After combining differentially expressed genes and modular genes, we selected overlapping genes as central genes ( image 3 A). Ovarian cancer data from the Kaplan Meier-Plotter database (http: / / kmplot.com / analysis / ) were used for survival analysis of central genes. The OS (overall survival) forest plot of these genes is shown in image 3 As shown in B, and the progression-free survival (PFS) forest plot of these genes is also shown in image 3 As shown in C, and the progression-free survival (PFS) forest plot of these genes is also shown in image 3 C shown. A total of 13 genes were identified, including BUB1B, KIF20A, MCM2, CEP55, MTHFD2, FOXM1, PBK, CDKN2A, PTX3, RACGAP1, MEOX1, UBE2C, and IDH2, which were associated with OS and PFS in ovarian cancer patients ( image 3 D).

[0065] Conclusion: BUB1B, KIF20A, MCM2, CEP55, MTHFD2, FOXM1, PBK, CDKN2A, PTX3, RACGAP1, MEOX1, U...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel application of PTX-3 in medical detection. According to the invention, a series of scientific bioinformatics analysis methods are used as the screening method of the differential protein of the ovarian cancers and the normal ovarian tissues, the PTX-3 gene or PTX-3 protein is used as a marker for detecting or diagnosing the ovarian cancer and as an identification index of an ovarian cancer tumor, a junctional tumor and a normal ovarian epithelium for the first time, and the novel application of the PTX-3 gene or the PTX-3 protein as the ovarian cancer recurrence and metastasis monitoring marker is provided for the first time. The novel application of PTX-3 makes up for the deficiency of ovarian cancer recurrence and metastasis monitoring index deficiency, and has good clinical application value.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and more specifically relates to a new application of PTX-3 in medical detection. Background technique [0002] Ovarian cancer is one of the most important malignant tumors in gynecology. Due to the lack of typical symptoms and effective biomarkers in the early stage, about 70% of patients are in the advanced stage at the time of clinical diagnosis. Epithelial ovarian neoplasms are the main pathological type, accounting for 80-95% of ovarian cancers. Patients with epithelial ovarian cancer are sensitive to chemotherapy drugs, and most advanced patients can usually achieve clinical remission after receiving standard treatment, but many patients have a poor prognosis due to recurrence and drug resistance. Therefore, exploring early diagnosis and prognostic biomarkers of ovarian cancer has important clinical significance. [0003] With the development of gene chips and high-throughput sequenc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/574
CPCG01N33/57449G01N33/57484
Inventor 王涛朱保坤白璐田野马长剑
Owner 沈阳金域医学检验所有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap